Company: NDRA
Filing Date: 2025-10-17
Form Type: PRE 14A
Source: 0001654954-25-011931
Chunk: 47

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-17
Form: PRE 14A
Chunk 47
---
 to reduce litigation costs associated with frivolous lawsuits, the Board of Directors adopted and declared the advisability of the Exculpation Amendment.

Approval of this Proposal 5 is not contingent on the approval of any other proposal.

Effect of the Exculpation Amendment

If Proposal 5 is adopted by our stockholders, we expect that the Exculpation Amendment will be filed with the Delaware Secretary of State and become effective shortly after such stockholder approval. Once the Exculpation Amendment has become effective, it will continue to protect our directors from personal liability for monetary damages for breaches of the duty of care and will also protect certain of our officers from personal liability for monetary damages for breaches of the duty of care (other than claims by or in the right of the corporation). Our Board of Directors nevertheless may, at any time prior to the filing of the Exculpation Amendment with the Delaware Secretary of State and the Exculpation Amendment becoming effective, notwithstanding stockholder approval of the Exculpation Amendment, abandon the Exculpation Amendment without further action by our stockholders.

| 35 |

Vote Required for Approval

The affirmative vote of our stockholders holding a majority in voting power of our common stock and Series A Preferred Stock (voting on an as converted to common stock basis) issued and outstanding on the record date, voting together as a single class is required to approve and adopt the Exculpation Amendment.

Board Recommendation

The Board of Directors unanimously recommends a vote “FOR” the approval and adoption of the Exculpation Amendment as described in this Proposal 5. The Board of Directors retains the discretion to abandon, and not implement, the Exculpation Amendment at any time before it becomes effective.

<div align='center'>PROPOSAL 6 – SECOND AMENDMENT TO 2016 OMNIBUS INCENTIVE PLAN</div>

Background

The Company currently maintains the ENDRA Life Sciences Inc. 2016 Omnibus Incentive Plan, as amended (the “2016 Plan”), which was originally adopted by the Board and approved by our stockholders in 2016 and subsequently amended at our 2018 annual meeting of stockholders.

Under the 2016 Plan, the Company initially reserved 1,345,074 shares of common stock for issuance to eligible employees, officers, non-employee directors, consultants, and advisors of the Company or of any affiliate. This amount of shares represented 18% of the total number of shares of Company common stock outstanding (